Remove 2026 Remove Pharma Remove Prescription
article thumbnail

Colorado drug review board finds J&J's Stelara unaffordable, teeing up potential statewide price cap

Fierce Pharma

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the review board unanimously agreed that Stelara is "unaffordable," the drug could be subject to an upper payment limit in the state.

article thumbnail

Jazz Pharma uses flying pig for huge grey area DTC

World of DTC Marketing

billion by 2026. Jazz Pharmaceuticals has introduced a new prescription medication for patients with sleep apnea/narcolepsy that “helped adults get up to 9 hours of improved wakefulness in clinical studies at 12 weeks” and they’re using a flying pig on their DTC. This DTC is an embaressment.

Pharma 181
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Health consumers: A long way off

World of DTC Marketing

Our healthcare system makes too much money for insurers, PBM’s and pharma companies to change. By 2026, national health expenditures will reach $5.7 It’s simple: people trust each other more than pharma companies who they view with a high degree of skepticism. It’s a good read but ignores a simple fact.

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. Ipsen’s CVR offer includes $0.30

Biopharma 110
article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

This product would be a more potent prescription version than the OTCs, Casberg notes. The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen. Starting in 2026, the provision will affect 10 Part D drugs.

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. pharma sales in 2020) and the size of 340B discounts (25-50%), companies may see significantly reduced revenues for important products. The 340B battle will rage on.

article thumbnail

Why we need to support healthcare’s vital acceleration

pharmaphorum

While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. In pharma, for instance, the global top 20 companies accounted for only about 35% market share in 1981, yet this figure had jumped to 65% by 2022.